157 related articles for article (PubMed ID: 27565326)
1. Oxaliplatin-rapamycin combination was superior to mono-drug in treatment of hepatocellular carcinoma both in vitro and in vivo.
Li XZ; Sun YL; Cao LQ; Li MJ
Neoplasma; 2016; 63(6):880-887. PubMed ID: 27565326
[TBL] [Abstract][Full Text] [Related]
2. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
Kang HG; Wang BZ; Zhang J; Liu MR; Li YX
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):197-203. PubMed ID: 27863926
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
4. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
5. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
6. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
7. Total alkaloids of Rubus aleaefolius Poir inhibit hepatocellular carcinoma growth in vivo and in vitro via activation of mitochondrial-dependent apoptosis.
Zhao J; Chen X; Lin W; Wu G; Zhuang Q; Zhong X; Hong Z; Peng J
Int J Oncol; 2013 Mar; 42(3):971-8. PubMed ID: 23338043
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
10. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
[TBL] [Abstract][Full Text] [Related]
11. Celastrus orbiculatus Extracts Inhibit Human Hepatocellular Carcinoma Growth by Targeting mTOR Signaling Pathways.
Qian YY; Li WY; Yan Y; Zhao XY; Yang T; Fang CC; Hou JJ; Liu YQ
Chin J Integr Med; 2019 Nov; 25(11):845-852. PubMed ID: 31127506
[TBL] [Abstract][Full Text] [Related]
12. CC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.
Xie Z; Wang J; Liu M; Chen D; Qiu C; Sun K
PLoS One; 2017; 12(3):e0173252. PubMed ID: 28334043
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat enhances the anticancer effect of oxaliplatin on hepatocellular carcinoma cells.
Liao B; Zhang Y; Sun Q; Jiang P
Cancer Med; 2018 Jan; 7(1):196-207. PubMed ID: 29239146
[TBL] [Abstract][Full Text] [Related]
14. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
15. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
18. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
19. Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3.
Zhang G; Zeng X; Zhang R; Liu J; Zhang W; Zhao Y; Zhang X; Wu Z; Tan Y; Wu Y; Du B
Phytomedicine; 2016 Nov; 23(12):1329-1336. PubMed ID: 27765352
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Sun J; Tan CJ; Dai Z
Expert Opin Investig Drugs; 2009 Nov; 18(11):1595-604. PubMed ID: 19780708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
